Your browser doesn't support javascript.
loading
Implementation of an In-House Platform for Rapid Screening of SARS-CoV-2 Genome Variations.
Zare Ashrafi, Farzane; Mohseni, Marzieh; Beheshtian, Maryam; Fattahi, Zohreh; Ghodratpour, Fatemeh; Keshavarzi, Fatemeh; Behravan, Hanieh; Kalhor, Marzieh; Jalalvand, Khadijeh; Azad, Maryam; Koshki, Mahdieh; Jafarpour, Ali; Ghaziasadi, Azam; Abdollahi, Alireza; Kiani, Seyed Jalal; Ataei-Pirkooh, Angila; Rezaei Azhar, Iman; Bokharaei-Salim, Farah; Haghshenas, Mohammad Reza; Babamahmoodi, Farhang; Mokhames, Zakiye; Soleimani, Alireza; Ziaee, Masood; Javanmard, Davod; Ghafari, Shokouh; Ezani, Akram; Ansari Moghaddam, Alireza; Shahraki-Sanavi, Fariba; Hashemi Shahri, Seyed Mohammad; Azaran, Azarakhsh; Yousefi, Farid; Moattari, Afagh; Moghadami, Mohsen; Fakhim, Hamed; Ataei, Behrooz; Nasri, Elahe; Poortahmasebi, Vahdat; Varshochi, Mojtaba; Mojtahedi, Ali; Jalilian, Farid; Khazeni, Mohammad; Moradi, Abdolvahab; Tabarraei, Alijan; Piroozmand, Ahmad; Yahyapour, Yousef; Bayani, Masoumeh; Aboofazeli, Amir; Ghafari, Parsa; Keramat, Fariba; Tavakoli, Mahsa.
Afiliación
  • Zare Ashrafi F; Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
  • Mohseni M; Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
  • Beheshtian M; Kariminejad-Najmabadi Pathology & Genetics Center, Tehran, Iran.
  • Fattahi Z; Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
  • Ghodratpour F; Kariminejad-Najmabadi Pathology & Genetics Center, Tehran, Iran.
  • Keshavarzi F; Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
  • Behravan H; Kariminejad-Najmabadi Pathology & Genetics Center, Tehran, Iran.
  • Kalhor M; Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
  • Jalalvand K; Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
  • Azad M; Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
  • Koshki M; Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
  • Jafarpour A; Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
  • Ghaziasadi A; Kariminejad-Najmabadi Pathology & Genetics Center, Tehran, Iran.
  • Abdollahi A; Kariminejad-Najmabadi Pathology & Genetics Center, Tehran, Iran.
  • Kiani SJ; Research Center for Clinical Virology, Tehran University of Medical Sciences, Tehran, Iran.
  • Ataei-Pirkooh A; Gerash Amir-al-Momenin Medical and Educational Center, Gerash University of Medical Sciences, Gerash, Iran.
  • Rezaei Azhar I; Research Center for Clinical Virology, Tehran University of Medical Sciences, Tehran, Iran.
  • Bokharaei-Salim F; Department of Pathology, School of Medicine, Imam Khomeini Hospital, Tehran University of Medical Sciences, Iran.
  • Haghshenas MR; Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Babamahmoodi F; Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Mokhames Z; Research Center for Clinical Virology, Tehran University of Medical Sciences, Tehran, Iran.
  • Soleimani A; Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Ziaee M; Department of Medical Microbiology, Antimicrobial Resistance Research Center, Communicable Diseases Institute, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
  • Javanmard D; Department of Medical Microbiology, Antimicrobial Resistance Research Center, Communicable Diseases Institute, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
  • Ghafari S; Department of Molecular Diagnostic, Emam Ali Educational and Therapeutic Center, Alborz University of Medical Sciences, Karaj, Iran.
  • Ezani A; Department of Infectious Diseases, Imam Ali hospital, Alborz University of Medical Sciences, Karaj, Iran.
  • Ansari Moghaddam A; Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.
  • Shahraki-Sanavi F; Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.
  • Hashemi Shahri SM; Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.
  • Azaran A; Qazvin Deputy of Treatment Reference Laboratory, Qazvin University of Medical Sciences, Qazvin, Iran.
  • Yousefi F; Health Promotion Research Center, Zahedan University of Medical Science, Zahedan, Iran.
  • Moattari A; Health Promotion Research Center, Zahedan University of Medical Science, Zahedan, Iran.
  • Moghadami M; Infection Disease and Tropical Medicine Research Center, Zahedan University of Medical Science, Zahedan, Iran.
  • Fakhim H; Department of Medical Virology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
  • Ataei B; Department of Infectious Diseases, School of Medicine, Razi Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
  • Nasri E; Department of Virology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Poortahmasebi V; Health policy research center, Shiraz University of medical sciences, Shiraz, Iran.
  • Varshochi M; Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Mojtahedi A; Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Jalilian F; Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Khazeni M; Department of Bacteriology and Virology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Moradi A; Infectious and Tropical Disease Research Center, Tabriz University of Medical Science, Tabriz, Iran.
  • Tabarraei A; Microbiology Department, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
  • Piroozmand A; Department of Medical Virology, Faculty of Medicine, Hamadan University of Medical sciences, Hamadan, Iran.
  • Yahyapour Y; Booali lab, Molecular & Virology Diagnostic Section, Qom, Iran.
  • Bayani M; Golestan University of Medical Sciences, Gorgan, Iran.
  • Aboofazeli A; Golestan University of Medical Sciences, Gorgan, Iran.
  • Ghafari P; Department of Microbiology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
  • Keramat F; Infectious Diseases and Tropical Medicine Research Center, Babol University of Medical Sciences, Babol, Iran.
  • Tavakoli M; Infectious Diseases and Tropical Medicine Research Center, Babol University of Medical Sciences, Babol, Iran.
Arch Iran Med ; 26(2): 69-75, 2023 02 01.
Article en En | MEDLINE | ID: mdl-37543926
ABSTRACT

BACKGROUND:

Global real-time monitoring of SARS-CoV-2 variants is crucial to controlling the COVID-19 outbreak. The purpose of this study was to set up a Sanger-based platform for massive SARS-CoV-2 variant tracking in laboratories in low-resource settings.

METHODS:

We used nested RT-PCR assay, Sanger sequencing and lineage assignment for 930-bp of the SARS-CoV-2 spike gene, which harbors specific variants of concern (VOCs) mutations. We set up our platform by comparing its results with whole genome sequencing (WGS) data on 137 SARS-CoV-2 positive samples. Then, we applied it on 1028 samples from March-September 2021.

RESULTS:

In total, 125 out of 137 samples showed 91.24% concordance in mutation detection. In lineage assignment, 123 out of 137 samples demonstrated 89.78% concordance, 65 of which were assigned as VOCs and showed 100% concordance. Of 1028 samples screened by our in-house method, 78 distinct mutations were detected. The most common mutations were SD614G (21.91%), SP681R (12.19%), SL452R (12.15%), ST478K (12.15%), SN501Y (8.91%), SA570D (8.89%), SP681H (8.89%), ST716I (8.74%), SL699I (3.50%) and SS477N (0.28%). Of 1028 samples, 980 were attributed as VOCs, which include the Delta (B.1.617.2) and Alpha (B.1.1.7) variants.

CONCLUSION:

Our proposed in-house Sanger-based assay for SARS-CoV-2 lineage assignment is an accessible strategy in countries with poor infrastructure facilities. It can be applied in the rapid tracking of SARS-CoV-2 VOCs in the SARS-CoV-2 pandemic.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Tipo de estudio: Diagnostic_studies / Screening_studies Idioma: En Revista: Arch Iran Med Año: 2023 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Tipo de estudio: Diagnostic_studies / Screening_studies Idioma: En Revista: Arch Iran Med Año: 2023 Tipo del documento: Article